On Wednesday, Shares of Ford Motor Co. (NYSE:F), gained 1.37% to $15.50.
There’s no mistaking the wicked sound or aggressive looks of the all-new Shelby® GT350R-C that Ford declared recently would see its first official track time at Watkins Glen this weekend.
Ford Shelby GT350R-C, the competition version of the reincarnated icon, will compete in the IMSA Continental Tire SportsCar Challenge, a showdown of the most popular – and accessible – performance cars from around the world.
The GT350R production car was unveiled in January, and is one of more than 12 new vehicles Ford Performance will bring to market through 2020. Since its introduction, sports car enthusiasts have eagerly awaited the debut of a racing version.
Both production and race car versions feature the first-ever production car V8 from Ford with a flat-plane crankshaft. This unique layout – typically reserved for the world’s most exotic sports cars – assisted create the most powerful naturally aspirated engine Ford has ever produced.
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories.
Shares of Kinder Morgan, Inc. (NYSE:KMI), inclined 0.05% to $39.45, during its last trading session.
Kinder Morgan (KMI) has been able to grow its dividends sequentially over recent quarters despite the weakness in energy prices. Its 1Q15 dividend per share grew ~6.7% quarter-over-quarter, driven by growing fee-based cash flows.
According to Wall Street analysts’ estimates, KMI’s dividend is predictable to grow 2.7% quarter-over-quarter (or QoQ) in 2Q15 and ~15.3% year-over-year by the end of 2015 contrast to 2014. Analysts’ dividend growth estimates are in line with administration dividend guidance of 15% growth for full year 2015 over full year 2014.
According to company SEC filings, the administration has revealed insider transactions. , According to the information revealed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Kinder Morgan, Inc., Kean Steven J, had purchased 12,000 shares in a transaction dated on June 15, 2015. The transaction was executed at $39.38 per share with total amount equaling $472,560. Kinder Morgan, Inc. (NYSE:KMI) remains a strong buy in the latest set of rankings. The shares has received an average rating of 1.44 by 16 analysts. Zacks has advised to Sell for the short term with a rating of 4.
Kinder Morgan, Inc. operates as an energy infrastructure and energy company in North America. The company operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments.
Health care stocks dropped in afternoon trade Wednesday, with the NYSE Health Care Sector Index slumping about 0.5% and shares of health care companies in the S&P 500 down over 0.6% as a group.
But one of the Healthcare stock, Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), ended its last trade with 2.22% gain, and closed at $8.30.
Synergy Pharmaceuticals, declared the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation (IBS-C).
The phase 3 IBS-C program comprises two randomized, 12-week, double-blind, placebo-controlled pivotal trials conducted in the United States and each trial is predictable to enroll about 1050 adult patients with IBS-C. Patients with IBS-C are defined by Rome III Criteria as having a history of constipation and abdominal pain for at least 6 months, counting hard or lumpy stools for 25% or more of defecations, loose or watery stools for 25% or less of defecations, and abdominal pain or discomfort for 3 days or more per month for the last 3 months. The primary efficacy endpoint for both trials is the percentage of patients who are Overall Responders during the 12 week treatment period. An Overall Responder, as defined by the FDA, is a patient who is a weekly responder (i.e. meets both the abdominal pain intensity reduction and stool frequency enhance criteria in the same week) for at least 6 of the 12 treatment weeks.
Synergy initiated the first phase 3 IBS-C trial in December 2014. The phase 3 IBS-C program was designed to support regulatory submission in the US.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
